生物医药产业上市公司投资效率评价与优化研究  

Research on the Evaluation and Optimization of Investment Efficiency of Listed Companies in the Biomedical Industry

作　　者：尤俊达 YOU Junda(Business School of Shenyang University,Shenyang 110042,China)

机构地区：[1]沈阳大学商学院,辽宁沈阳110042

出　　处：《商业观察》2024年第36期62-65,78,共5页BUSINESS OBSERVATION

基　　金：辽宁社科规划基金课题(L20BGL009)资助。

摘　　要：文章深入分析了生物医药企业投资效率的评价与提升策略,构建了一套针对生物医药产业的投资效率评估体系。通过应用DEA模型,对2018—2022年间20家生物医药上市公司的投资效率进行了系统评估。评估结果显示,这些公司的投资效率普遍偏低,其均值大致位于0.88~0.97的范围内。为了更全面地理解投资效率的动态变化,文章还采用了Malmquist指数模型进行测算,得出生物医药产业的全要素生产率变动平均值为0.99,显示出整个产业在投资效率方面存在不足。进一步对财务报告的深入剖析显示,企业在研发领域的投入不足是技术进步缓慢的关键因素。针对这一问题,文章提出了一系列旨在提高生物医药产业投资效率的建议,这些建议涵盖了技术进步、生产制造以及经营管理等多个方面。This article discusses the evaluation and optimization strategies of investment efficiency in biomedical companies,establishes an investment efficiency evaluation system for the biomedical industry,and applies the DEA model to evaluate the investment efficiency of 20 listed companies in the biomedical industry from 2018 to 2022.The study has found that the average investment efficiency of biomedical listed companies is between 0.88 and 0.97,indicating a relatively low investment efficiency.The Malmquist index model is used to calculate the dynamic changes in investment efficiency,and it is found that the average change in total factor productivity is 0.99,indicating that the overall investment efficiency of the biomedical industry is needed to be improved.Through further analysis of financial reports,it is found that insufficient research and development expenses are an important reason for slow technological progress.The article proposes suggestions to improve the investment efficiency of the biomedical industry from the aspects of technological progress,production and manufacturing,and operation and management.

关 键 词：投资效率 DEA-Malmquist指数模型 生物医药 上市公司 

分 类 号：F406.7[经济管理—产业经济]